Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer

被引：0
|
作者：
Mariangela Manzoni
Sara Mariucci
Sara Delfanti
Bianca Rovati
Monica Ronzoni
Fotios Loupakis
Silvia Brugnatelli
Carmine Tinelli
Eugenio Villa
Alfredo Falcone
Marco Danova
机构：
[1] Fondazione IRCCS Policlinico S. Matteo,S.C. Oncologia
[2] Istituto Scientifico S. Raffaele,Oncologia Medica
[3] Oncologia 2 Universitaria,Dipartimento di Oncologia, dei Trapianti e delle Nuove Tecnologie in Medicina
[4] Azienda Ospedaliero-Universitaria Pisana,Unità di Epidemiologia Clinica e Biometria
[5] Fondazione IRCCS Policlinico S. Matteo,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2012年 / 138卷
关键词：
Biomarkers; Circulating endothelial cells; Apoptosis; Angiogenesis; Colorectal cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1187 / 1196
页数：9
相关论文
共 50 条
  • [41] KRAS codon 12 and 13 mutations in metastatic colorectal cancer: Predictive marker in first-line bevacizumab-based chemotherapy
    Cunha Pereira, T.
    Salgueiro, F.
    Monteiro, A.
    Felix Soares, R.
    Macedo, F.
    Jacinto, P.
    Paulo, J.
    Bonito, N.
    Marques, M.
    Ribeiro, J.
    Sousa, G.
    ANNALS OF ONCOLOGY, 2020, 31 : S163 - S164
  • [42] CIRCULATING ENDOTHELIAL CELLS IN METASTATIC COLORECTAL CANCER: POTENTIAL BIOMARKERS OF RESPONSE AND RESISTANCE TO ANTIANGIOGENETIC THERAPY
    Mariucci, S.
    Rovati, B.
    Chatzileontiadou, S.
    Manzoni, M.
    Loupakis, F.
    Delfanti, S.
    Bencardino, K.
    Valentino, F.
    Brugnatelli, S.
    Ronzoni, M.
    Danova, M.
    CYTOMETRY PART A, 2010, 77A (02) : 198 - 198
  • [43] Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients
    A Abajo
    V Boni
    I Lopez
    M Gonzalez-Huarriz
    N Bitarte
    J Rodriguez
    R Zarate
    E Bandres
    J Garcia-Foncillas
    British Journal of Cancer, 2012, 107 : 287 - 290
  • [44] Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients
    Abajo, A.
    Boni, V.
    Lopez, I.
    Gonzalez-Huarriz, M.
    Bitarte, N.
    Rodriguez, J.
    Zarate, R.
    Bandres, E.
    Garcia-Foncillas, J.
    BRITISH JOURNAL OF CANCER, 2012, 107 (02) : 287 - 290
  • [45] Circulating tumour cells as a predictive factor for response to systemic chemotherapy in patients with advanced colorectal cancer
    Lankiewicz, Silke
    Zimmermann, Silke
    Hollmann, Christiane
    Hillemann, Tina
    Greten, Tim F.
    MOLECULAR ONCOLOGY, 2008, 2 (04) : 349 - 355
  • [46] Use of circulating endothelial cells to predict response to FOLFOX4 plus bevacizumab in metastatic colorectal cancer
    Matsusaka, S.
    Mizunuma, N.
    Suenaga, M.
    Chin, K.
    Shinozaki, E.
    Watanabe, T.
    Kawazoe, Y.
    Kuboki, Y.
    Terui, Y.
    Hatake, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [47] Efficacy of bevacizumab-based treatment in early-onset treatment-naive metastatic colorectal cancer patients: An ARCAD database analysis
    Jin, Zhaohui
    Dixon, Jesse G.
    Hubbard, Joleen M.
    Eng, Cathy
    Lieu, Christopher Hanyoung
    Fiskum, Jack
    Saltz, Leonard B.
    Hurwitz, Herbert I.
    Venook, Alan P.
    Schmoll, Hans-Joachim
    Fuchs, Charles S.
    Hecht, J. Randolph Randolph
    Cremolini, Chiara
    Diaz-Rubio, Eduardo
    Punt, Cornelis J. A.
    Tebbutt, Niall C.
    Heinemann, Volker
    Yoshino, Takayuki
    De Gramont, Aimery
    Shi, Qian
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [48] Detection and monitoring of circulating endothelial cells, circulating tumor cells and disseminated tumor cells during neoadjuvant breast cancer treatment including bevacizumab
    Mathiesen, R. R.
    Borgen, E.
    Saetersdal, A. B.
    Fangberget, A.
    Schirmer, C.
    Stav, I.
    Fagerland, M. W.
    Wist, E.
    Engebraten, O.
    Naume, B.
    CANCER RESEARCH, 2013, 73
  • [49] Visceral fat as a predictive marker of response to bevacizumab -based treatment in metastatic colorectal cancer.
    Miyamoto, Yuji
    Sakamoto, Yasuo
    Watanabe, Masayuki
    Baba, Hideo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [50] Circulating endothelial cells (CECs) in metastatic colorectal cancer (mCRC) patients (pts) treated with bevacizumab (BEV) and sorafenib.
    Lafky, J. M.
    Bot, B. M.
    Morlan, B. W.
    Anderson, S. K.
    Kimlinger, T. K.
    Halling, T. M.
    Kumar, S.
    Reynolds, J. T.
    Stella, P. J.
    Dakhil, S. R.
    Loui, W. S.
    Alberts, S. R.
    Grothey, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345